is aripiprazole fda approved for ocd? no, and the label shows it

“Our epiprozole, for example, is not FDA approved for OCD.”

a host said on Psychopharmacology and Psychiatry Updates, 2026-10-23, at 01:24. hear it in context → the speaker cited: FDA approval status.

the episode: Second-Generation Antipsychotics for OCD Augmentation (at 01:24). we link the show's own page; we do not re-host audio.

first, the part that holds

the host is right: aripiprazole is not FDA approved for obsessive-compulsive disorder. ocd is not among the indications on the reference prescribing information for the oral tablets, or on a current generic oral label.

what we found when we went and looked

we pulled the current FDA prescribing information for the reference oral aripiprazole product (application NDA021436) through openFDA. it lists five indications: schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and tourette's disorder. ocd shows up only once, in the suicidality warning, which pools pediatric antidepressant trials in depression, ocd and other disorders. it is not an indication. a separate generic oral label we pulled lists fewer indications and also leaves out ocd. the off-label evidence is real, though: a 2015 meta-analysis of placebo-controlled trials found the largest effect for aripiprazole as an add-on to serotonin reuptake inhibitors in treatment-resistant ocd, but that came from only 2 trials with 79 patients.

assertion by assertion

both directions

for the speaker: the FDA label itself. the indications section of the reference oral product names five conditions, and ocd is not one of them. its only appearance is in a warning about antidepressant trials, which is not an approval. a generic oral label we pulled also leaves out ocd.

against: nothing in the label contradicts the host. the one thing listeners could miss is the difference between approval and evidence. randomized trials of aripiprazole added to a serotonin reuptake inhibitor in treatment-resistant ocd exist, and a meta-analysis found it had the largest effect among the antipsychotics studied. so 'not approved' is not the same as 'not studied' or 'not used'. we did not hear the full segment, so we cannot say whether the host made that distinction on air.

what this cannot say

we pulled two openFDA label records, one reference and one generic oral. we did not open every formulation's label or the full Drugs@FDA supplement history, so we are relying on the current reference indications section as the authoritative list. a label shows what the FDA approved. it does not show why a manufacturer never applied for an ocd indication, or how often aripiprazole is prescribed for ocd. the off-label efficacy figure rests on 2 small trials (n=79), so the large effect size is imprecise. we did not check approval status outside the US.

sources, each one fetched and read

1. US Food and Drug Administration, openFDA drug label record, aripiprazole tablets prescribing information, application NDA021436 (record updated 2026-10-23) What we read there: indicated for the treatment of: schizophrenia; acute treatment of manic and mixed episodes associated with bipolar I disorder; adjunctive treatment of major depressive disorder; irritability associated with autistic disorder; treatment of tourette's disorder. ocd appears only in the suicidality warning: 'the pooled analyses of placebo-controlled trials in children and adolescents with MDD, Obsessive Compulsive Disorder (OCD), or other psychiatric disorders...' Fetched 2026-10-24 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.application_number:"NDA021436"&limit=1
2. US Food and Drug Administration, openFDA drug label record, generic oral aripiprazole prescribing information (record updated 2026-10-23) What we read there: 'aripiprazole is indicated for the treatment of: schizophrenia, irritability associated with autistic disorder, treatment of tourette's disorder.' ocd is mentioned only in the warning on suicidal thoughts and behaviors, not as an indication. Fetched 2026-10-24 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"aripiprazole"+AND+openfda.route:"ORAL"&limit=1
3. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 2015. PMC4576518 What we read there: 14 trials, n=491, pooled effect size -0.64. 'aripiprazole (hedges's g=-1.35), haloperidol (hedges's g=-0.82), and risperidone (hedges's g=-0.59) significantly outperformed placebo.' aripiprazole came from 2 trials with 79 patients. Fetched 2026-10-24 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC4576518/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam